Pharmaceutical innovation in the United States. Factors affecting future performance

Area of Science:

• Pharmaceutical industry economics
• Healthcare policy
• Research and development funding

Background:

• The US pharmaceutical industry has experienced 50 years of growth, driven by high investment returns.
• A regulatory model combining stringent testing with market-based pricing has supported company investment in research and development (R&D).

Purpose of the Study:

• To analyze the impact of managed-care cost-containment strategies on pharmaceutical R&D investment.
• To examine the sustainability of current pharmaceutical industry growth models.

Main Methods:

• Analysis of historical industry financial performance.
• Review of US regulatory and healthcare market policies.
• Assessment of R&D investment trends in relation to pricing strategies.

Main Results:

• High returns have historically fueled pharmaceutical R&D investment.
• Managed-care cost-containment measures are creating financial pressures.
• These pressures may hinder the recovery of R&D expenses.

Conclusions:

• Current cost-containment strategies pose a threat to pharmaceutical companies' ability to recoup R&D investments.
• Future pharmaceutical innovation may be impacted by these financial challenges.